Announced Fri, 11 Sept, 2026 · 13:42 IST
USFDA completes successful inspection at Senores subsidiary Apnar Pharma's Vadodara facility
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.1%1-day move
₹1468.00
prior close
₹1454.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+1.0+1.0+0.6-3.1-6.7-4.5-5.2-5.1-5.9-4.6———
Up moveDown movePending
AI summary
The USFDA inspected the manufacturing facility of Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited in Vadodara from September 7 to September 11, 2026. The inspection concluded successfully with only one minor procedural observation and no GMP-related observations. Apnar Pharma will submit its response within the stipulated timeframe.
Likely market impact
Positive regulatory outcome. Clean USFDA inspection supports uninterrupted manufacturing and export operations, strengthening compliance standing.